Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2006

01-01-2006 | Original Article

Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131

Authors: Tone Cappelen, Jan Frede Unhjem, Anne Lise Amundsen, Gunnhild Kravdal, Ivar Følling

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2006

Login to get access

Abstract

Purpose

The purpose of this study was twofold: (1) to measure the radiation exposure to family members of out-patients with thyrotoxicosis treated with radioiodine, 131I, using the recommendations from the European Commission (EC) guidance and age-specific periods for behaviour restrictions; (2) to use the results to identify necessary restrictions to ensure recommended dose constraints.

Methods

The study population comprised 76 family members (46 adults and 30 children below the age of 18) of 42 patients. The patients were treated with an average activity of 417 MBq (range 260–600 MBq). They received oral and written EC recommendations about behaviour restrictions (translated into Norwegian). On the day of treatment we repeated the oral instructions to the patient and an adult family member. The time periods for restrictions were 14 days for children aged 0–10 years, 7 days for persons aged 11–59 years and 3 days for persons aged 60 years and older. Family members wore a thermoluminescent dosimeter (TLD) on each wrist day and night for 2 weeks. The doses received were adjusted to give an estimate of the expected values if the TLDs had been worn indefinitely.

Results

Radiation doses well below the recommended dose constraints were measured for all adult family members and children, except one 2-year-old child; in the latter case the mother probably did not comply with the instructions given.

Conclusion

The radiation dose to family members of thyrotoxic patients treated with up to 600 MBq of radioiodine is well below recommended dose constraints if EC instructions are given and compliance is adequate. The duration of restrictions for various age groups used in this study may be considered when establishing guidelines in Norway.
Literature
1.
Hoefnagel CA, Clarke SE, Fischer M, Chatal JF, Lewington VJ, Nilsson S, et al. EANM Radionuclide Therapy Committee. Eur J Nucl Med 1999;26:277–82CrossRefPubMed
2.
Beckers C, Alexander WD, Burger A, Lazarus J, Krenning E, Schlumberger M, et al. A report of the European Thyroid Associations’s committee on radioiodine therapy in thyrotoxicosis. 131I therapy for thyrotoxicosis towards 2000. Eur J Nucl Med 1996;23:BP13–5CrossRef
3.
Lassman M, Hänscheid H, Schelper LF. Measurement of incorporation in family members of patients with benign thyroid disease after radioiodine therapy. Nuklearmedizin 1998;37:120–3PubMed
4.
Schomaecker K, Fisher T, Gaidouk, M, Schicha H. Exhalation of 131I after radioiodine therapy: time dependence and chemical form. Proceedings of the 47th annual meeting, Society of Nuclear Medicine (abstract). J Nucl Med 2000;41 Suppl:251P
5.
Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am J Public Health 1978;68:225–30PubMed
6.
Council of the European Union. Guideline 96/29/EURATOM to determine basic directions for health protection of public and workers against ionizing radiation related dangers. Leafl Eur Commun 1996;L159/1
7.
Council of the European Union. Directive on the health protection of individuals against the dangers of ionizing radiation in relation to medical exposures. 97/43/Euratom OJ 1997;L180:22–7
8.
International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21(1–3)
9.
European Commission. Radiation protection 97: radiation protection following iodine-131 therapy (exposures due to outpatients or discharged inpatients). Luxembourg, Belgium: Office for Official Publications of the European Communities; 1998
10.
Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, et al. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centers in Flanders (Belgium). Eur J Nucl Med 1998;25:1368–76CrossRefPubMed
11.
Barrington SF, O’Doherty MJ, Kettle AG, Thomson WH, Mountford PJ, Burell DN, et al. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med 1999;26:686–92CrossRefPubMed
12.
Thomson WH, Mills AP, Smith NB, Mostafa AB, Notghi A, Harding LK. Radiation doses to patient’s relatives: day and night components and their significance in terms of ICRP 60. Eur J Nucl Med 1993;993 poster nr 697
13.
Barrington SF, Kettle AG, Mountford PJ, Thomson WH, Batchelor S, Burrell DN, et al. Radiation exposure of patient’s children at home post I-131 administration. Eur J Nucl Med 1995;22:798
14.
Mathieu I, Caussin J, Smeesters P, Wambersie A, Beckers C. Doses in family members after 131I treatment. Lancet 1997;350:1074–5CrossRef
15.
O’Doherthy MJ, Kettle AG, Eustance CNP, Mountford PJ Coakley AJ. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nucl Med Commun 1993;14:160–8PubMed
16.
Wasserman HJ, Klopper JF. Analysis of radiation doses received by the public from 131I treatment of thyrotoxic outpatients. Nucl Med Commun 1993;14:756–60PubMed
17.
Cappelen T, Unhjem JF. Patients with hyperthyroidism treated with radioactive iodine and exposures to family members. Eur J Nucl Med Mol Imaging 2004;31:P828, S457
18.
Regulations No. 1362 of 21. November 2003 on Radiation Protection and Use of Radiation (Norwegian Radiation Protection Regulation)
Metadata
Title
Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131
Authors
Tone Cappelen
Jan Frede Unhjem
Anne Lise Amundsen
Gunnhild Kravdal
Ivar Følling
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-1888-7

Other articles of this Issue 1/2006

European Journal of Nuclear Medicine and Molecular Imaging 1/2006 Go to the issue

Image of the Month

Visualisation of sodium-iodide symporter

Original Article

FDG-PET and CT characterization of adrenal lesions in cancer patients

Editorial Commentary

99mTc-tetrofosmin as a prognostic agent?

Original Article

Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer

Original Article

Memory-provoked rCBF-SPECT as a diagnostic tool in Alzheimer’s disease?

Editorial Commentary

Myocardial ischaemia and metabolic memory